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Transforming growth factor  (TGF-) is a cytokine which has been shown to suppress the antimycobac-
terial immune responses of humans and experimental animals. In this study, the contributions of TGF- to
cytokine production in vivo were investigated by using the established guinea pig model of tuberculous pleurisy.
Mycobacterium bovis BCG-vaccinated guinea pigs were injected intrapleurally with heat-killed virulent Myco-
bacterium tuberculosis. Eight days following induction of an antigen-specific pleural effusion, guinea pigs were
injected intrapleurally with anti-TGF-1 or isotype control antibody. The following day, pleural exudates were
removed, and the fluid volume and characteristics of the infiltrating cells were determined. Pleural fluid was
analyzed for total interferon (IFN) and tumor necrosis factor (TNF) protein levels by using appropriate
bioassays. RNA from pleural effusion cells was examined to determine TGF-1, TNF-, IFN-, and interleu-
kin-8 mRNA levels by using real-time PCR. Proliferative responses of pleural effusion lymphocytes were
examined in response to concanavalin A and purified protein derivative (PPD) in vitro. Treatment with
anti-TGF-1 resulted in decreased pleural fluid volume and decreased cell numbers in the pleural space along
with an increased percentage of lymphocytes and a decreased percentage of neutrophils. The bioactive TNF
protein levels in pleural fluid were increased in guinea pigs treated with anti-TGF-1, while the bioactive IFN
protein concentrations were not altered. Expression of TGF-1 and TNF- mRNA was significantly increased
following TGF-1 neutralization. Finally, PPD-induced proliferative responses of pleural cells from anti-TGF-
1-treated animals were significantly enhanced. Thus, TGF-1 may be involved in the resolution of this local,
mycobacterial antigen-specific inflammatory response.
Mycobacterium tuberculosis is the leading cause of death
from an infectious disease worldwide, with the exception of
human immunodeficiency virus. It is estimated that approxi-
mately one-third of the world’s population is infected with this
organism (4). Tuberculous pleurisy is the predominant ex-
trapulmonary manifestation of tuberculosis and is caused by a
severe delayed-type hypersensitivity response to mycobacteria
or mycobacterial antigens that have escaped from lung granu-
lomas and invaded the pleural space (13). A guinea pig model
that mimics tuberculous pleurisy was developed in our lab (3,
30) and has been useful for examining the cell-mediated im-
mune response to mycobacteria in the context of an antigen-
specific inflammatory exudate. This model allows components
of the immune system to be manipulated in vivo in order to
examine their roles in this delayed-type hypersensitivity re-
sponse. One cytokine likely to be involved is transforming
growth factor  (TGF-), due to its known contributions to
processes such as fibrosis and resolution of inflammatory re-
sponses (37). Tuberculous pleurisy is a manifestation of tuber-
culosis that is self-healing (31), which implies that the local
immune response results in successful control of the mycobac-
teria. Increased levels of TGF-1 have been observed in the
pleural fluid of tuberculous pleurisy patients compared with
the levels in pleural exudates with other etiologies (27). Fur-
thermore, elevated levels of TGF- are also observed in the
plasma of tuberculous pleuritis patients (29). In patients with
recurrent pleural effusions, typically due to cancer, pleurodesis
is performed, in which the pleural space is obliterated by the
induction of pleural fibrosis (21). TGF- has been used to
induce pleurodesis in animal models and appears to be a good
candidate for use in humans (20, 22, 23, 25).
TGF- levels have also been examined in patients with pul-
monary tuberculosis. Elevated levels of TGF- were found in
plasma of pulmonary tuberculosis patients compared with the
levels in healthy contacts and patients who had undergone
successful treatment for tuberculosis (29). Additionally, puri-
fied protein derivative (PPD) stimulation of peripheral blood
mononuclear cells (PBMC) from tuberculosis patients on che-
motherapy for less than 1 month resulted in significantly in-
creased TGF- protein production compared with the produc-
tion in cells from patients on chemotherapy for more than 1
month and cells from healthy controls (16). Unstimulated
PBMC from tuberculosis patients also produced significantly
larger amounts of TGF- than PBMC from healthy tuberculin-
positive individuals produced, and granulomas from tubercu-
losis patients stained positive for TGF- (33). Increased
TGF- levels have been associated with increased severity of
tuberculosis. PBMC from patients with advanced pulmonary
tuberculosis produced significantly higher levels of TGF- in
the absence or presence of whole sonicated antigen from M.
tuberculosis than PBMC from patients with mild to moderate
disease and PBMC from healthy controls produced (11).
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In a previous study, it was shown that the TGF-1 concen-
trations in the pleural exudate of guinea pigs with experimental
tuberculous pleurisy were relatively low during the first 2 days
postinduction and increased throughout the experiment, peak-
ing between days 7 and 9 postinduction (3). In this study,
TGF-1 levels in the pleural fluid were neutralized 8 days
postinduction by intrapleural injection of anti-TGF-1 anti-
body, and the effect on the cellular nature and cytokine content
of the pleural effusion was examined 1 day later.
MATERIALS AND METHODS
Reagents. Chicken anti-human TGF-1, the human TGF-1 DuoSet enzyme-
linked immunosorbent assay (ELISA) development system, and control chicken
immunoglobulin Y were obtained from R&D Systems (Minneapolis, Minn.).
RPMI 1640 medium supplemented with HEPES buffer, 10% Hartley guinea pig
serum (Harlan Laboratories, Indianapolis, Ind.), 2-mercaptoethanol (10 M),
L-glutamine (2 M), penicillin (100 U/ml), and streptomycin (100 g/ml) was
used in all experiments. Concanavalin A (ConA) (Sigma, St. Louis, Mo.) and M.
tuberculosis PPD (Statens Seruminstitut, Copenhagen, Denmark) were used to
stimulate lymphoproliferation.
Animals and vaccination. Outbred Hartley strain guinea pigs from Charles
River Breeding Laboratories, Inc. (Wilmington, Mass.) were used in this study.
Guinea pigs were vaccinated via intradermal injection of 0.1 ml (103 CFU) of a
viable Mycobacterium bovis BCG (Danish 1331 strain; Statens Seruminstitut)
culture. All protocols were approved by the Texas A&M University Laboratory
Animal Care Committee.
Preparation of mycobacteria and pleurisy induction. A vial of live M. tuber-
culosis H37Rv (ATCC 27294; American Type Culture Collection, Manassas,
Va.) was removed from storage at 80°C and rapidly thawed. The bacterial
suspension was vortexed and sonicated with an Ultrasonics sonicator (Heat
Systems-Ultrasonics, Inc., Plainview, N.Y.) for 45 to 60 s at an output setting of
8.0 to disrupt bacterial clumps. The bacteria were then heat killed by incubation
in an 80°C water bath for 2 h and diluted in a sterile 0.9% sodium chloride
solution to a final concentration of 1.8  107 CFU/ml. Five weeks after vacci-
nation (day 0), guinea pigs were anesthetized by using a previously described
protocol (30), and pleurisy was induced by injection of 1 ml of heat-killed M.
tuberculosis H37Rv bilaterally into the pleural cavity. On day 8 postinduction,
guinea pigs were anesthetized, and 12.5 g of anti-TGF-1 or the same concen-
tration of control chicken immunoglobulin Y was injected bilaterally into the
pleural cavity. The animals were euthanized 24 h later.
Necropsy and cell isolation. Guinea pigs were euthanized by intraperitoneal
injection of an overdose (100 mg/kg) of sodium pentobarbital (Sleepaway; Fort
Dodge Laboratories, Inc., Fort Dodge, Iowa). Fluid in the pleural cavity was
collected, and the area was washed two times with ice-cold phosphate-buffered
saline to remove accumulated inflammatory cells. The pleural fluid was centri-
fuged at 200  g for 15 min to remove the cells. The fluid was then transferred
to a new conical tube and centrifuged at 1,400  g for 20 min to remove all
cellular debris, and it was stored at 80°C until it was needed. All cells from the
pleural space were combined, and the erythrocytes were lysed with ACK lysing
buffer (0.15 M NH4Cl, 0.01 M KHCO3, 0.1 mM Na2EDTA), followed by two
washes with phosphate-buffered saline.
Differential cell counts. Cells obtained from the pleural cavity were charac-
terized to determine the proportion of major leukocyte types. Cells were centri-
fuged onto silanated glass slides (CSA-100; PGC Scientifics, Gaithersburg, Md.)
at 140  g for 5 min (Cytospin 2; Shandon Southern Instrument, Inc., Sewickley,
Pa.). Cells were stained with Diff-Quik (Dade Behring Inc., Newark, Del.) and
viewed under a light microscope in order to determine the relative immune cell
composition by cell morphology.
Histopathology. Diaphragms and mediastinae were taken from pleuritic
guinea pigs and fixed in 10% buffered formalin for examination of the pleural
lining. Tissues were embedded in paraffin and sectioned to obtain 5-m sections,
and the sections were stained with hematoxylin and eosin for histopathological
examination.
Measurement of cytokine proteins in pleural fluid. In order to determine
TGF-1 protein concentrations, pleural fluid was analyzed by an ELISA (human
TGF-1 DuoSet ELISA development system; R&D Systems). Prior to the assay,
pleural fluid samples were activated by using the manufacturer’s protocol for
activation of serum samples. Use of human TGF-1 reagents in guinea pigs is
justified because the mature guinea pig TGF-1 protein (GenBank accession no.
AF191297) exhibits 98% sequence homology with mature human TGF-1, and
we and several other investigators have successfully used human TGF-1 re-
agents, including antibody, for guinea pig studies (8, 9, 17, 32, 42).
The guinea pig fibroblast cell line 104C1 (ATCC CRL-1405; American Type
Culture Collection) and the challenge virus encephalomyocarditis virus (ATCC
VR-129B) were used to determine the concentrations of bioactive interferon
(IFN) in the pleural fluid as previously described (41). Briefly, 104C1 cells were
seeded onto 96-well plates at a concentration of 3  104 cells/well and incubated
at 37°C in the presence of 5% CO2 for 24 h. Human IFN- (400 U/ml) and
pleural fluid samples were twofold serially diluted, added (50%, vol/vol) to the
cells, and incubated for 20 to 24 h. Encephalomyocarditis virus was then added
to the plate at a concentration of 900 PFU/well, and the plate was incubated for
24 to 30 h. WST-1/1-methoxy PMS (Dojindo, Kumamoto, Japan) was added to
the cells and incubated for 2 to 4 h at 37°C. Color development was stopped with
1 N H2SO4. The optical density at 450 nm was measured with a microtiter plate
reader with a 630-nm reference filter.
The mouse fibroblast cell line L929 (ATCC CCL-1; American Type Culture
Collection) was used to determine the concentrations of total bioactive tumor
necrosis factor (TNF) in the pleural fluid by the method of Espevik et al. (15),
with some modifications. Briefly, L929 cells were seeded onto 96-well plates (4
104 cells/well) and grown to confluence overnight at 37°C in the presence of 5%
CO2. Human TNF- and pleural fluid samples were twofold serially diluted and
added (25%, vol/vol) to the cells. Actinomycin D (8 g/ml) was added to each
well, and then the plates were incubated for approximately 20 h. Cell viability was
determined as described above for the IFN bioassay.
Total RNA isolation and real-time PCR. Total RNA was isolated from cells by
using RNeasy columns, and contaminating DNA was removed by on-column
treatment with RNase-free DNase (QIAGEN, Valencia, Calif.). Reverse tran-
scription, performed by using TaqMan reverse transcription reagents, and real-
time PCR, performed by using SYBR Green I double-stranded DNA binding
dye (Applied Biosystems, Foster City, Calif.), were carried out by using the
previously described protocol (3, 26). The real-time primers used for guinea pig
TGF-1, IFN-, TNF-, interleukin 8 (IL-8), and 18S RNA were the primers
described previously (3). The level of induction of mRNA was determined from
the threshold cycle values normalized for 18S RNA expression and then nor-
malized to the value derived from healthy, pleuritis-free animals.
Lymphoproliferation. Cells from the pleural effusion were analyzed to deter-
mine their ability to proliferate in response to ConA (10 g/ml) and PPD (12.5
and 25 g/ml) in vitro. Pleural cells were seeded onto 96-well plates (2  105
cells/well) in medium alone or in the presence of ConA or PPD and cultured by
using our standard procedure (7). [3H]thymidine was added at a concentration of
1 Ci/well for the final 6 h of incubation. Cells were harvested onto glass fiber
filters, and proliferative activity was quantified by determining the number of
counts per minute with a liquid scintillation counter (LS8000; Beckman Instru-
ments, Inc., Fullerton, Calif.). Stimulation indices were calculated by dividing the
number of counts per minute from stimulated cells by the number of counts per
minute from unstimulated cells.
Statistical analysis. A t test was used to examine statistical differences between
anti-TGF-1-treated and control guinea pigs at the 95% confidence interval. The
statistical tests were performed with SAS software (release 8.01; SAS Institute,
Inc., Cary, N.C.).
RESULTS
Cell and fluid accumulation in control and anti-TGF-1-
treated guinea pigs. Eight days after pleurisy induction, guinea
pigs were injected with anti-TGF-1 or control antibody. One
day later, the guinea pigs were euthanized, and accumulated
fluid and cells were removed from the pleural cavity. Figure 1
shows the total volumes of fluid and the numbers of cells that
accumulated in the pleural space of control and treated guinea
pigs. Large amounts of fluid were present in the pleural cavities
of control guinea pigs, while there was a dramatic decrease in
the fluid volume in the pleural spaces of anti-TGF-1-treated
guinea pigs (Fig. 1A) (P  0.01). Similar to the increased fluid
volume seen in control animals, the total numbers of recover-
able cells were higher in the control guinea pigs than in the
anti-TGF-1-treated animals (Fig. 1B). Injection of anti-
TGF-1 resulted in significantly decreased total cell numbers
in the pleural effusions of treated guinea pigs (P 	 0.01). The
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concentration of cells in the pleural fluid was actually higher in
the anti-TGF-1-treated guinea pigs than in the controls (Fig.
1C); however, the difference was not significant.
Differential cell counts and histopathology of pleural tis-
sues. A portion of the pleural exudate cells was centrifuged
onto glass slides and stained with Diff-Quik to determine the
percentages of monocytes, lymphocytes, and neutrophils. The
resident cells in the pleural cavities of two healthy guinea pigs
were found to consist of 63.6 and 65% large monocytes, 2%
lymphocytes, and 0 and 0.3% neutrophils. The remaining cells
were eosinophils (34.7 and 32.7%). Figure 2 shows that in
control antibody-treated guinea pigs with experimental tuber-
culous pleurisy, neutrophils were by far the predominant cell
type present in the pleural fluid, while much lower numbers of
monocytes and lymphocytes were present. On the other hand,
in pleuritic guinea pigs treated with anti-TGF-1, lymphocytes
and neutrophils were present at roughly equal proportions,
and there were fewer monocytes. Compared with controls,
treatment with anti-TGF-1 resulted in a statistically signifi-
cant increase in the proportion of lymphocytes and a statisti-
cally significant decrease in the proportion of neutrophils
present in the pleural space (P  0.05). The remaining cell
types found in the pleural cavities of guinea pigs were eosin-
ophils (4.57% 
 1% in controls and 2.38% 
 0.86% in anti-
TGF-1-treated animals) and Kurloff cells (6.95% 
 0.68% in
controls and 3.09% 
 0.96% in anti-TGF-1-treated animals).
Anti-TGF-1 treatment did not significantly affect the propor-
tions of these cells found in the pleural space.
Hematoxylin- and eosin-stained paraffin sections of pleural
tissues taken from control and anti-TGF-1-treated guinea
pigs were evaluated histopathologically. Guinea pigs in both
groups developed well-formed granulomas with extensive fi-
brosis in the diaphragmatic and mediastinal pleurae. No dif-
ferences were observed between the groups with respect to the
percentage of the tissue affected, the number of intralesional
organisms, the level of necrosis, the inflammatory cell types, or
the formation of organized granulomas.
Cytokine profiles in pleural fluid of guinea pigs. During the
course of experimental tuberculous pleurisy in guinea pigs, the
TGF-1 protein concentrations in the pleural fluid were high-
est between days 7 and 9 (3). In order to assess whether
neutralization of TGF-1 during this time affected the produc-
tion of other cytokines, pleural fluid was analyzed for total IFN
and TNF protein concentrations. Figure 3 shows the total
levels of proteins in pleural exudates of guinea pigs rather than
the concentrations as the amount of pleural fluid in control
antibody-treated guinea pigs was significantly greater than the
amount found in anti-TGF-1-treated guinea pigs. The total
bioactive IFN protein levels in the pleural fluid were lower, but
not significantly lower, as a result of anti-TGF-1 treatment
(Fig. 3A). The bioactive TNF protein levels were below the
level of detection in pleural fluid from the control guinea pigs.
However, bioactive TNF was detected in two of four animals in
the anti-TGF-1-treated group (mean, 2,366 pg/guinea pig),
suggesting that removal of TGF-1 enhanced TNF protein
production during experimental tuberculous pleurisy.
In order to ensure that treatment of guinea pigs with anti-
TGF-1 actually removed TGF-1 from the pleural space,
TGF-1 protein levels in the pleural fluids of control and
treated guinea pigs were measured. As shown in Fig. 3B, in-
jection of anti-TGF-1 into the pleural cavity of guinea pigs on
day 8 significantly lowered the TGF-1 levels in the pleural
fluid on day 9 (P  0.01).
Effect of neutralizing TGF-1 on in vivo expression of
mRNA of several cytokines. To examine the effect of removal
FIG. 1. Accumulation of fluid and cells in pleural exudates of
guinea pigs with tuberculous pleurisy. Fluid accumulation (A), cell
accumulation (B), and cell concentration (C) were measured in control
pleuritic guinea pigs and guinea pigs receiving experimental injections
of anti-TGF-1. Cells were stained with trypan blue and counted with
a hemocytometer. The bars and error bars indicate averages and stan-
dard errors of the means for three of four animals. An asterisk indi-
cates that there is significant difference between the number of cells or
fluid volume and the number of cells or fluid volume in control guinea
pigs.
FIG. 2. Differential counts of pleural exudate cells from pleuritic
control and anti-TGF-1-treated guinea pigs. Cells were stained with
Diff-Quik as described in Materials and Methods, and cell morphology
was used to determine which cell types were present in the pleural
fluid. Two counts (300 cells each) were performed, and the number of
each cell type was divided by the total number of cells to obtain the
percentage. The bars indicate the percentages of the total cell popu-
lation recovered from the pleural space for three or four animals, and
the error bars indicate the standard errors of the means. An asterisk
indicates that there is a significant difference between the percentage
of a cell type and the percentage in the controls.
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of TGF-1 on the cytokine response of pleural exudate cells,
total RNA was isolated from cells obtained from the pleural
space of pleuritic guinea pigs and was analyzed for expression
of TGF-1, TNF-, IFN-, and IL-8 mRNA by real-time PCR.
As shown in Fig. 4A, the levels of TGF-1 mRNA in anti-
TGF-1-treated guinea pigs were greater than the levels in
control animals (P 	 0.056). Likewise, Fig. 4B shows that the
levels of TNF- mRNA in anti-TGF-1-treated guinea pigs
were significantly greater than the levels in control animals (P
 0.05). The levels of IFN- mRNA expression are shown in
Fig. 4C. Treatment of guinea pigs with anti-TGF-1 resulted in
an increase in IFN- mRNA expression compared with the
expression in the controls. However, due to large differences in
IFN- expression between animals in each group, the differ-
ence between groups was not significant. Finally, as Fig. 4D
shows, IL-8 mRNA expression was not affected by treatment of
guinea pigs with anti-TGF-1.
Pleural cell proliferation is enhanced in the absence of in
vivo TGF-1. Cells from the pleural space were collected and
stimulated in vitro with ConA or with two concentrations of
PPD (12.5 and 25 g/ml) for 4 days to determine the prolifer-
ative responses of antigen-specific T lymphocytes in the exu-
date. Figure 5 shows that anti-TGF-1 treatment resulted in
enhanced proliferative responses of pleural effusion lympho-
cytes to ConA and both doses of PPD. While there was an
obvious increase in proliferation by cells from anti-TGF-1-
treated guinea pigs upon ConA stimulation, only the responses
to both PPD concentrations were significantly greater than the
responses of pleural cells from control animals (P  0.05).
FIG. 3. Cytokine protein levels in pleural fluids of control and
anti-TGF-1-treated guinea pigs. Total bioactive IFN (A) and TGF-1
(B) protein levels in pleural exudates of guinea pigs were measured.
Total IFN protein levels were analyzed by a bioassay, as described in
Materials and Methods, and are expressed in units per total volume of
fluid in the pleural space of each guinea pig. TGF-1 protein levels
were analyzed by an ELISA and are expressed in nanograms per total
volume of fluid in the pleural space of each guinea pig. The bars
indicate the means for three or four animals per day, and the error bars
indicate the standard errors of the means. An asterisk indicates that
there is a significant difference between the protein levels and the
levels in the control animals.
FIG. 4. Cytokine mRNA expression in pleural exudate cells from guinea pigs with tuberculous pleurisy. Expression of TGF-1 mRNA (A),
expression of TNF-mRNA (B), expression of IFN-mRNA (C), and expression of IL-8 mRNA (D) were measured in pleural fluid cells obtained
from control and anti-TGF-1-treated guinea pigs with experimental tuberculous pleurisy. The level of induction was determined from the
threshold cycle values normalized for 18S expression and then normalized to the values derived from resident pleural cells of healthy, pleuritis-free
animals. The bars indicate the means for three or four animals, and the error bars indicate the standard errors of the means. An asterisk indicates
that there is a significant difference between mRNA expression in cells from treated animals and mRNA expression in cells from control animals.
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DISCUSSION
Tuberculous pleurisy is an antigen-specific delayed-type hy-
persensitivity response that occurs in a confined, accessible
anatomical site and thus is ideal for studying the role of cyto-
kines in the immune response against mycobacterial antigens.
One regulatory cytokine that is of particular interest in this
context is TGF-. TGF- is a pluripotent cytokine that is
known to participate in both pro- and anti-inflammatory pro-
cesses (37). Some proinflammatory activities of TGF-1 in-
clude chemotactic activity for monocytes (39), neutrophils (5),
and lymphocytes (1), upregulation of cell surface integrin ex-
pression (38), and enhancement of expression of mRNA of
proinflammatory cytokines, including IL-1 (39), TNF, and IL-6
(35), in resting monocytes. Perhaps more well-known are the
immunosuppressive properties of TGF-1, including down-
regulation of IL-1 receptor (12) and simultaneous induction of
IL-1 receptor antagonist expression (36), suppression of proin-
flammatory cytokine production by various cell types (6, 14),
macrophage deactivation (10, 34), and suppression of T lym-
phocyte proliferation in response to mitogenic stimulation
(18).
In a recent study, TGF-1 protein concentrations in pleural
fluid during the first 9 days of experimentally induced tuber-
culous pleurisy in guinea pigs were examined (3). It was found
that the TGF-1 concentrations were approximately 3.2 to 4.8
ng/ml during the first 3 days and then significantly increased to
between 10 and 11.5 ng/ml on days 7 through 9 of the inflam-
matory response. The high levels of TGF-1 detected on days
7 through 9 prompted us to neutralize TGF-1 during this
period and examine the resulting effect on the cellular and
cytokine responses in the pleural space of guinea pigs. On the
one hand, the results presented here suggest that TGF-1 acts
in a proinflammatory manner. Neutralization of TGF-1 re-
sulted in reduced fluid and cell accumulation in the pleural
space compared with the accumulation in the controls (Fig. 1).
One explanation for the increased numbers of cells in control
guinea pigs with tuberculous pleurisy may be that TGF-1
continued to induce chemotaxis of cells, particularly neutro-
phils, since the number of these cells was significantly greater
in control guinea pigs than in anti-TGF-1-treated animals
(Fig. 2). Alternatively, cell death may have been responsible
for the lower numbers of cells in anti-TGF-1-treated guinea
pigs. Previous research has demonstrated that TGF-1 en-
hances survival of human neutrophils (19), suggesting a possi-
ble explanation for the decreased number of neutrophils in the
anti-TGF-1 treated guinea pigs.
On the other hand, TGF-1 appears to have an anti-inflam-
matory effect in the guinea pig tuberculous pleuritis model. For
instance, the concentration of lymphocytes in the pleural cavity
was significantly decreased in the absence of TGF-1 (Fig. 2).
Additionally, the proliferative responses of these cells to PPD
stimulation in vitro when TGF-1 levels were reduced by an-
tibody treatment were dramatically stronger than the re-
sponses of pleural cells from control guinea pigs (Fig. 5), pos-
sibly indicating that TGF-1 plays a role in the resolution of
the adaptive immune response against mycobacterial antigens.
Bioactive TNF protein levels and TNF- mRNA expression
(Fig. 4) were also increased in guinea pigs treated with anti-
TGF-1, suggesting that TGF-1 normally may limit the pro-
duction of TNF to promote the resolution of the inflammatory
response. Finally, while IFN protein concentrations were
slightly lower in the anti-TGF-1-treated guinea pigs, expres-
sion of IFN- mRNA in pleural cells was somewhat increased
in the absence of TGF-1 (Fig. 3 and 4). Neither of these
differences was significant, suggesting that TGF-1 did not
have a significant effect on the presence of IFN- in tubercu-
lous pleurisy.
Previous studies have demonstrated that TGF- is present in
the pleural exudates of patients with pleuritis having various
etiologies, including tuberculosis (27, 29). In addition, investi-
gators have examined the ability of TGF-2 to act as a pleu-
rodesing agent to stop the recurrence of pleuritis (22, 25).
However, to our knowledge, no one has altered the levels of
TGF- in pleural exudates to examine the role of this cytokine
in the inflammatory response that occurs during pleuritis. We
attempted to define the role of TGF-1 in the mycobacterium-
specific delayed-type hypersensitivity response as a predomi-
nantly proinflammatory or immunosuppressive response. In-
stead, we confirmed the dichotomous nature of this cytokine.
McCartney-Francis and Wahl (28) suggested that low levels
of TGF- at the beginning of an inflammatory response initi-
ate recruitment to and activation of cells at the site of injury.
TGF- levels continually increase at the site, and as lympho-
cytes and macrophages differentiate, they become suppressed
by this cytokine, leading to resolution of the inflammatory
response and decreasing levels of TGF-. Based on previous
studies of induction of pleuritis in response to mycobacteria or
their products in guinea pigs (2, 24, 30, 40), we believed that
the pleuritis might resolve itself by day 9. It is possible, how-
ever, that the pleuritis might persist for several more days.
Thus, during this period of the antigen-specific delayed-type
hypersensitivity reaction, TGF- may both sustain the inflam-
matory response and act to resolve it. It may induce chemotaxis
of neutrophils and enhance their survival, while it suppresses
new expression of TNF- and IFN- mRNA by differentiated
macrophages and lymphocytes, respectively. Finally, it may
further suppress lymphocytes by inhibiting their antigen-spe-
FIG. 5. Proliferation of pleural exudate cells from pleuritic guinea
pigs in control and anti-TGF-1-treated groups. Pleural exudate cells
from guinea pigs with experimental tuberculous pleurisy were cultured
for 96 h in the presence of 10 g of ConA per ml, 12.5 g of PPD per
ml (PPD-12.5), or 25 g of PPD per ml (PPD-25). Proliferative re-
sponses are expressed as the stimulation index (counts per minute for
stimulated cells/counts per minute for unstimulated cells) for individ-
ual animals. The bars indicate the means for three or four animals, and
the error bars indicate the standard errors of the means. An asterisk
indicates that the proliferative response is significantly greater than
that of cells from control guinea pigs.
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cific proliferative response to PPD. Therefore, while TGF-1
may be involved in proinflammatory activities, we believe that
this cytokine plays an essential role in the resolution of tuber-
culous pleurisy in guinea pigs.
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